2012-09-18 08:06:22 - Fast Market Research recommends "Osteoarthritis Pain - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'Osteoarthritis Pain - Pipeline Review, H2 2012', provides an overview of the Osteoarthritis Pain therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. 'Osteoarthritis Pain - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the

indicated disease.


Full Report Details at
- www.fastmr.com/prod/463865_osteoarthritis_pain_pipeline_review_h ..


Scope

* A snapshot of the global therapeutic scenario for Osteoarthritis Pain.
* A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Osteoarthritis Pain therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Osteoarthritis Pain Therapeutic Products under Development, Key Players in Osteoarthritis Pain Therapeutics, Osteoarthritis Pain Pipeline Overview, Osteoarthritis Pain Pipeline, Osteoarthritis Pain Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteoarthritis Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Osteoarthritis Pain
Osteoarthritis Pain Therapeutics under Development by Companies
Osteoarthritis Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Osteoarthritis Pain Therapeutics - Products under Development by Companies
Osteoarthritis Pain Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Osteoarthritis Pain Therapeutics Development
Genzyme Corporation
Johnson & Johnson
Abbott Laboratories
Allergan, Inc.
Sanofi-Aventis
Eli Lilly and Company
BioDelivery Sciences International, Inc.
Nektar Therapeutics
MedImmune LLC
Cephalon, Inc.
Menarini Group
BioChemics, Inc.
Addex Pharmaceuticals
Elite Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Array BioPharma Inc.
AnaMar Medical AB
Neurotune AG
IDEA AG
QRxPharma Limited
Iroko Pharmaceuticals, LLC
Winston Pharmaceuticals, Inc.
SantoSolve AS
Antibe Therapeutics, Inc.
Flexion Therapeutics
Afferent Pharmaceuticals, Inc.
Apimeds, Inc.
Osteoarthritis Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CEP-33237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX71943 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-11624 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELI-216 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vicodin CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nucynta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463865&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.